NASDAQ · TLRY

Tilray Brands, Inc.

$3.88 -$0.11 (-2.76%) 1D After hours

Key Metrics

$492.59M
Market cap
P/E · TTM
$858.28M
Revenue · TTM
−$1.34B
Net income
EPS · TTM $-12.26
Dividend yield
Free cash flow
Beta · 1Y 1.95
EBITDA · TTM
Gross margin 27.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Feb 26 high, the share price fell 51%.

    Peak close $7.99 on Feb 26; trough close $3.88 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -51%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 23
    The stock moved -11.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 23
  • Apr 22
    The stock moved +14.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 22

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$492.59M
Enterprise value
Shares outstanding123.5M
52-wk range$0.55 – $15.70
Avg volume · 20D26.6M
Net cash
Book value / share$14.20
IndustryMedicinal Chemicals & Botanical Products
ExchangeNASDAQ
About Tilray Brands, Inc.
IPO dateJan 23, 2015
Employees2842

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.57
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 27.7%
Operating -169.8%
Net -156.7%
FCF
ROE / ROIC -53.8% · -99.8%

Financial Health

Current ratio2.79
Quick ratio1.66
Debt / equity
Debt / EBITDA
Net cash
Working capital$461.22M

Cash Flow · TTM

Operating CF −$44.63M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-4.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-02-28 · computed by TickerWolf from SEC filings